• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • DeviceTalks Weekly
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » UPDATE: FDA panel OKs Bard’s Lutonix balloon

UPDATE: FDA panel OKs Bard’s Lutonix balloon

June 13, 2014 By Ingrid Mezo

FDA panel OKs Bard's Lutonix balloon

UPDATED June 13, 2014, with comments from panel members.

An FDA advisory panel yesterday recommended approval for the Lutonix drug-eluting balloon made by C.R. Bard (NYSE:BCR).

The FDA’s Circulatory Systems advisory panel unanimously voted in favor of the Lutonix DCB, finding it safe & effective and ruling that its benefits outweigh its risks, although they did note data for effectiveness was not robust and that further study of the device’s effects on women is needed.

"In terms of the [effectiveness] outcome, is it statistically significant? Yes. And is it clinically relevant? I’m hearing from the panel that it is moderately or modestly clinically important, but if you’re in that group that’s benefiting, I think overall the committee is saying that this is a clinically relevant endpoint that’s met statistical significance," said panel chairman Dr. Richard Page of the University of Wisconsin School of Medicine & Public Health.

The Lutonix DCB is an over-the-wire percutaneous PTA catheter with a paclitaxel-based drug coating on the surface of the balloon. It is compatible with a 0.035" guidewire and has balloon sizes ranging from 4 mm to 6 mm in diameter and 40 mm to 100 mm in length and is available in 75 cm, 100 cm and 130 cm working lengths, according to FDA background materials released ahead of the meeting.

Peripheral arterial disease (PAD), or plaque build-up in non-coronary blood vessels, is estimated to be present in around 8 million people in the U.S., including 12-20% of those individuals older than age 60.3, the federal watchdog agency noted. It narrows arteries, compromises blood flow to lower extremities, causes leg pain and can lead to disability and amputation.

Current treatment options include use of PTA alone and other permanently placed drug eluting stents, but restenosis remains a general concern.

"I work in this area and there’s a great unmet need here, and I wish the efficacy and safety were a little more robust, but I voted yes, I do believe in the data," said Dr. Daniel Simon of New Jersey’s Vascular Access Center at West Orange.

Dr. Edwin Gravereaux, of Brigham and Women’s Hospital in Boston, agreed.

"It certainly proved to be as safe as balloon angioplasty, it possibly met the endpoint for mild improvement and I look forward to seeing what it can do in the future," Gravereaux said.

Lutonix was developed as device-drug combination that is not a permanent implant, but aims to reduce restenosis compared to PTA alone. If the FDA follows its panel’s recommendation, it would be the first non-permanent drug-device combination approved for treating new, or not previously stented, restenotic lesions in the U.S.

In terms of a post-approval study, the panel was unanimous that more patients need to be collected for a minimum of 2 years; some panelists said they’d like to see a longer follow-up period.

"Specifically, we want to know more about longer-term in U.S. women, and we would really like to ideally understand the issue of the relationship to smoking. Some sort of relevant clinical endpoint would be nice, at least covered over the first couple of years," Page explained.

Several panelists noted that Lutonix could also be useful for indications beyond those studied so far.

"I urge the sponsor to increase the robustness of the database by increasing the numbers in the registry and also to go onto areas like acute ischemia, et cetera, because I do think this is promising," noted Dr. John Somberg of Rush University Medical Center in North Carolina.

Filed Under: Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: C.R. Bard, Peripheral

In case you missed it

  • CeQur raises $115M for wearable insulin delivery device
  • Survey shows solid medical device industry performance despite pandemic
  • Cardinal Health wins $58M federal PPE contract
  • SentiAR closes $5.1M Series A
  • Endologix acquires PQ Bypass
  • Could BrainCheck’s simple test help COVID long-haulers?
  • Feds halt J&J COVID-19 vaccine due to blood clot concern
  • BioCorp, Roche launch Mallya smart insulin pen in France
  • The top 5 pharma firms by reputation
  • Famed marathoner uses Abbott glucose sensor for training
  • Medical device companies put $3.6 billion in docs’ pockets, study finds
  • DiaSorin to buy Luminex for $1.8B
  • Genentech wins FDA approval for Xolair prefilled syringe
  • FDA slaps Class I label on rapid infuser recall
  • Microsoft spending $19.7B on Nuance and its AI for healthcare providers
  • Memic raises $96M to support surgical robot with humanoid-shaped arm
  • Heater-Cooler suit against LivaNova revived

RSS From Medical Design & Outsourcing

  • Micro to add plant in Costa Rica
    Contract manufacturer Micro today announced plans to open a new plant in Costa Rica. The 32,000 ft² facility will significantly increase Micro’s cleanroom assembly capacity, according to the Somerset, N.J.-based company. It will be located in the Zona Franca Metro business park and is expected to open in late 2021 with operations beginning in 2022.… […]
  • Survey shows solid medical device industry performance despite pandemic
    By Stewart Eisenhart, Emergo Group Medical device and IVD manufacturers report healthy performance over the course of 2020, but also faced significant operational and regulatory challenges related to the coronavirus pandemic. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s only and do not… […]
  • Cardinal Health wins $58M federal PPE contract
    Cardinal Health (NYSE: CAH) today said it has won a $57.8 million contract from the U.S. Dept. of Health and Human Services to support the Strategic National Stockpile. The Dublin, Ohio-based company received the contract, which includes options that if exercised by the HHS could reach $91.6 million, to store and distribute 80,000 pallets of… […]
  • Qosina adds single-use bioprocessing devices
    Qosina this week launched its product line for the single-use bioprocess industry. The new product line includes tube-to-tube bard connectors, luer fittings, check valves, tubing pinch clamps, tubing, steam thru connectors and more. Get the full story on our sister site, Medical Tubing + Extrusion. The post Qosina adds single-use bioprocessing devices appeared first on […]
  • Could BrainCheck’s simple test help COVID long-haulers?
    BrainCheck‘s eponymous mobile neurocognitive test can detect dementia and concussion. But it has a new application: post-COVID brain fog. Developed by neurologists at Baylor College of Medicine’s Eagleman Laboratory for Perception and Action, BrainCheck carries an FDA Class II Software as a Medical Device (SaMD) designation and can be used on a tablet or laptop… […]
  • XL Precision Technologies holding an April 28 webinar about laser tech
    XL Precision Technologies is holding an online webinar on April 28 at 8 a.m. Eastern time (1 p.m. U.K. time) about laser technology in medical device manufacturing. Register for the webinar here: https://bit.ly/XL-MER-Webinar2 Stockton-on-Tees, U.K.–based XL Precision Technologies provides laser welding, laser cutting of fine tubes and flat material and laser etching of components. It’s… […]
  • Medical device companies put $3.6 billion in docs’ pockets, study finds
    Medtech companies paid $3.62 billion for access to physicians — 10% more than drug companies did — from 2014 to 2017, according to new research. Device company payments to surgical specialists were significantly more tied to the surgeons’ Medicare billing than payments from drug companies to specialists, according to the study, which appears in the… […]
  • FDA slaps Class I label on rapid infuser recall
    The FDA today declared that the recall of an emergency infusion device kit is the most serious type. The recall covers three models of disposable sets made by Smisson-Cartledge Biomedical for its ThermaCor 1200 rapid infuser, which is used for fluid or bolus delivery. The system is made of a footswitch for hands-free fluid control,… […]
  • Cretex breaks ground on new plant north of Minneapolis
    Cretex Cos. last week broke ground on a new 245,000 ft2 medical device contract manufacturing plant in Brooklyn Park, Minn. Elk River, Minn.–based Cretex plans to complete facility construction by the end of the year. The company expects the facility by the end of 2022 to house its stamping, molding and tool design — and… […]
  • Resonetics to expand manufacturing in Costa Rica
    Resonetics announced today it has leased new manufacturing space in Costa Rica to more than double its production there. The space, in a building near its current site in the Coyol Free Zone business park in Alajuela, will be expanded and reconfigured to create a 45,000 ft² production site. The move comes after the company… […]
  • Are Black patients not getting LVADs as quickly as white patients?
    Researchers from the University of Missouri conducted a study that found disparities in treating Black and white patients with advanced heart failure. According to a news release, the study found that Black patients with advanced heart failure were more likely to receive a left ventricular assist device (LVAD) — a pump implanted into the chest… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS